Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Flamel Technologies S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Flamel Technologies S.A. - Product Pipeline Review - 2014', provides an overview of the Flamel Technologies S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Flamel Technologies S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Flamel Technologies S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Flamel Technologies S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Flamel Technologies S.A.'s pipeline products Reasons to buy - Evaluate Flamel Technologies S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Flamel Technologies S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Flamel Technologies S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Flamel Technologies S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Flamel Technologies S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Flamel Technologies S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Flamel Technologies S.A. Snapshot 5 Flamel Technologies S.A. Overview 5 Key Information 5 Key Facts 5 Flamel Technologies S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Flamel Technologies S.A. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Flamel Technologies S.A. - Pipeline Products Glance 12 Flamel Technologies S.A. - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Flamel Technologies S.A. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Flamel Technologies S.A. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 Flamel Technologies S.A. - Drug Profiles 15 aldesleukin biobetter 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 FT-105 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Drug for Cardiovascular Disorders 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 GLP-1 biobetter 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Proteins for Undisclosed Indication 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecules for Undisclosed Indication 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 somatropin biobetter 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 tigecycline biobetter 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Drug for Pain 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Drug for Respiratory Disorders 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Flamel Technologies S.A. - Pipeline Analysis 25 Flamel Technologies S.A. - Pipeline Products by Target 25 Flamel Technologies S.A. - Pipeline Products by Route of Administration 26 Flamel Technologies S.A. - Pipeline Products by Molecule Type 27 Flamel Technologies S.A. - Pipeline Products by Mechanism of Action 28 Flamel Technologies S.A. - Dormant Projects 29 Flamel Technologies S.A. - Discontinued Pipeline Products 30 Discontinued Pipeline Product Profiles 30 interferon alfa-2b biobetter 30 interferon beta-1a biobetter 30 Flamel Technologies S.A. - Company Statement 31 Flamel Technologies S.A. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Flamel Technologies S.A. - Key Manufacturing Facilities 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 37 Disclaimer 37
List of Tables Flamel Technologies S.A., Key Information 5 Flamel Technologies S.A., Key Facts 5 Flamel Technologies S.A. - Pipeline by Indication, 2014 7 Flamel Technologies S.A. - Pipeline by Stage of Development, 2014 8 Flamel Technologies S.A. - Monotherapy Products in Pipeline, 2014 9 Flamel Technologies S.A. - Partnered Products in Pipeline, 2014 10 Flamel Technologies S.A. - Partnered Products/ Combination Treatment Modalities, 2014 11 Flamel Technologies S.A. - Phase I, 2014 12 Flamel Technologies S.A. - Preclinical, 2014 13 Flamel Technologies S.A. - Unknown, 2014 14 Flamel Technologies S.A. - Pipeline by Target, 2014 25 Flamel Technologies S.A. - Pipeline by Route of Administration, 2014 26 Flamel Technologies S.A. - Pipeline by Molecule Type, 2014 27 Flamel Technologies S.A. - Pipeline Products by Mechanism of Action, 2014 28 Flamel Technologies S.A. - Dormant Developmental Projects,2014 29 Flamel Technologies S.A. - Discontinued Pipeline Products, 2014 30 Flamel Technologies S.A., Subsidiaries 34 Flamel Technologies S.A., Key Manufacturing Facilities 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.